Confronto
Cagrilintide vs. Tirzepatide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
1415456-99-3
2023788-19-2
Peso molecolare
4253.7 g/mol
4813 g/mol
Emivita
168 h
116 h
Sequenza
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMeccanismo d'azione
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
3
4
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Cagrilintide and Tirzepatide?
- Cagrilintide is classified as "Metabolico", while Tirzepatide is classified as "Metabolico". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Tirzepatide?
- The highest available evidence level is "RCT sull'uomo" for Cagrilintide and "RCT sull'uomo" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Tirzepatide in Germany and the United States?
- Germania: Cagrilintide — Non approvato, Tirzepatide — Su prescrizione. Stati Uniti: Cagrilintide — Non approvato, Tirzepatide — Su prescrizione. These are factual summaries with source and review date on the individual pages.